{
    "id": 22744,
    "fullName": "NECTIN4 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NECTIN4 positive indicates the presence of the NECTIN4 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 81607,
        "geneSymbol": "NECTIN4",
        "terms": [
            "NECTIN4",
            "EDSS1",
            "LNIR",
            "nectin-4",
            "PRR4",
            "PVRL4"
        ]
    },
    "variant": "positive",
    "createDate": "05/18/2016",
    "updateDate": "03/28/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6420,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, pancreatic cancer patient derived xenograft (PDX) model expressing Pvrl4 (Nectin-4) demonstrated sensitivity to Padcev (enfortumab vedotin-ejfv), resulting in inhibition of tumor growth (PMID: 27013195).",
            "molecularProfile": {
                "id": 23363,
                "profileName": "NECTIN4 positive"
            },
            "therapy": {
                "id": 4125,
                "therapyName": "Enfortumab vedotin-ejfv",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5571,
                    "pubMedId": 27013195,
                    "title": "Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27013195"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6421,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung adenocarcinoma cell line xenograft model expressing Pvrl4 (Nectin-4) demonstrated sensitivity to Padcev (enfortumab vedotin-ejfv), resulting in inhibition of tumor growth and tumor regression by 83.6% (PMID: 27013195).",
            "molecularProfile": {
                "id": 23363,
                "profileName": "NECTIN4 positive"
            },
            "therapy": {
                "id": 4125,
                "therapyName": "Enfortumab vedotin-ejfv",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5571,
                    "pubMedId": 27013195,
                    "title": "Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27013195"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6419,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer patient derived xenograft (PDX) model expressing Pvrl4 (Nectin-4) demonstrated sensitivity to Padcev (enfortumab vedotin-ejfv), resulting in inhibition of tumor growth and tumor regression by 62.9% (PMID: 27013195).",
            "molecularProfile": {
                "id": 23363,
                "profileName": "NECTIN4 positive"
            },
            "therapy": {
                "id": 4125,
                "therapyName": "Enfortumab vedotin-ejfv",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5571,
                    "pubMedId": 27013195,
                    "title": "Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27013195"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6417,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cells expressing Pvrl4 (Nectin-4) demonstrated sensitivity to Padcev (enfortumab vedotin-ejfv) in culture, resulting in decreased cell survival (PMID: 27013195).",
            "molecularProfile": {
                "id": 23363,
                "profileName": "NECTIN4 positive"
            },
            "therapy": {
                "id": 4125,
                "therapyName": "Enfortumab vedotin-ejfv",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5571,
                    "pubMedId": 27013195,
                    "title": "Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27013195"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6418,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a bladder cancer patient derived xenograft (PDX) model expressing Pvrl4 (Nectin-4) demonstrated sensitivity to Padcev (enfortumab vedotin-ejfv), resulting in inhibition of tumor growth and tumor regression (PMID: 27013195).",
            "molecularProfile": {
                "id": 23363,
                "profileName": "NECTIN4 positive"
            },
            "therapy": {
                "id": 4125,
                "therapyName": "Enfortumab vedotin-ejfv",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5571,
                    "pubMedId": 27013195,
                    "title": "Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27013195"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23363,
            "profileName": "NECTIN4 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}